146,491 Shares in Sana Biotechnology, Inc. (NASDAQ:SANA) Purchased by SG Americas Securities LLC

SG Americas Securities LLC bought a new stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 146,491 shares of the company's stock, valued at approximately $239,000. SG Americas Securities LLC owned 0.07% of Sana Biotechnology at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. FMR LLC increased its stake in Sana Biotechnology by 16.3% in the 3rd quarter. FMR LLC now owns 31,609,175 shares of the company's stock valued at $131,494,000 after buying an additional 4,438,949 shares during the period. State Street Corp increased its stake in shares of Sana Biotechnology by 4.2% in the third quarter. State Street Corp now owns 6,627,320 shares of the company's stock worth $27,570,000 after acquiring an additional 269,274 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Sana Biotechnology by 9.6% during the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company's stock worth $13,175,000 after acquiring an additional 276,055 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Sana Biotechnology by 11.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company's stock valued at $4,359,000 after purchasing an additional 105,382 shares during the last quarter. Finally, Barclays PLC grew its stake in Sana Biotechnology by 126.6% in the third quarter. Barclays PLC now owns 318,910 shares of the company's stock valued at $1,325,000 after purchasing an additional 178,179 shares in the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares of the company's stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 31.10% of the company's stock.

Sana Biotechnology Trading Down 8.7 %

Sana Biotechnology stock traded down $0.26 on Monday, reaching $2.73. 3,522,071 shares of the stock were exchanged, compared to its average volume of 13,520,750. Sana Biotechnology, Inc. has a twelve month low of $1.52 and a twelve month high of $12.00. The firm has a fifty day moving average price of $2.63 and a two-hundred day moving average price of $3.68. The stock has a market cap of $609.53 million, a PE ratio of -1.95 and a beta of 1.60.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SANA has been the subject of a number of recent research reports. JMP Securities downgraded Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research note on Tuesday, November 5th. HC Wainwright raised their price objective on shares of Sana Biotechnology from $8.00 to $11.00 and gave the company a "buy" rating in a research report on Wednesday, January 8th. Finally, TD Cowen raised Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Sana Biotechnology currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.25.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.